The Flow Cytometry Unit provides extensive support for NCI clinical protocols by providing diagnostic testing for leukemia and lymphoma in patients either on NCI clinical protocols or undergoing testing to determine eligibility for said protocols. The Flow Cytometry Unit provides clinical flow cytometric evaluation of blood, bone marrow, fine needle aspirates, tissue biopsies and body fluids for hematolymphoid neoplasia in NCI and NIH patients. The majority of flow cytometric testing performed by the Flow Cytometry Unit involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated by various clinical protocols. Significant effort in the unit is devoted to delivery of numerous unique protocol mandated assays that are not offered by commercial laboratories. The Flow Cytometry Unit is also actively engaged in education of the NIH staff and medical community at large in the proper utility of flow cytometry in medical practice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICSC009372-20
Application #
8350177
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
2011
Total Cost
$1,414,990
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Herndon, Thomas M; Chen, Shih-Shih; Saba, Nakhle S et al. (2017) Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leukemia 31:1340-1347
Keeney, Michael; Wood, Brent L; Hedley, Benjamin D et al. (2017) A QA program for MRD testing demonstrates that systematic education can reduce discordance among experienced interpreters. Cytometry B Clin Cytom :
Salem, Dalia; Stetler-Stevenson, Maryalice; Yuan, Constance et al. (2016) Myeloma minimal residual disease testing in the United States: Evidence of improved standardization. Am J Hematol 91:E502-E503
Wolniak, Kristy; Goolsby, Charles; Choi, Sarah et al. (2016) Report of the results of the International Clinical Cytometry Society and American Society for Clinical Pathology workload survey of clinical flow cytometry laboratories. Cytometry B Clin Cytom :
Niemann, Carsten U; Herman, Sarah E M; Maric, Irina et al. (2016) Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study. Clin Cancer Res 22:1572-82
Rawstron, Andy C; Paiva, Bruno; Stetler-Stevenson, Maryalice (2016) Assessment of minimal residual disease in myeloma and the need for a consensus approach. Cytometry B Clin Cytom 90:21-5
Preffer, Frederic I; Yuan, Constance M; Lin, Pei et al. (2016) Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease. Cytometry B Clin Cytom 90:9-10
Kreitman, Robert J; Stetler-Stevenson, Maryalice; Jaffe, Elaine S et al. (2016) Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. Clin Cancer Res 22:310-8
Lee, Daniel W; Kochenderfer, James N; Stetler-Stevenson, Maryalice et al. (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517-28
Stetler-Stevenson, Maryalice; Paiva, Bruno; Stoolman, Lloyd et al. (2015) Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom :

Showing the most recent 10 out of 66 publications